Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Functional investigations of the cells of the immune system (3rd part) Further analytical methods based on antigenantibody interactions MHC typing Examination of the hypersensitivity reactions (allergy and other hypersensitivity reactions) (The pro5.exe (4414KB) is an executable animation file which can be started from the “MHC multimer” slide of this slide show) (review/revise) Receptor crosslinking (immediate) phosphorilation steps - Western blot - Bead array (seconds-minutes) Antigen receptors (TCR, BCR), and different other receptors (e.g. cytokine receptors)ic Ca2+ increase - FACS, microscopy Gene activation - RT-PCR Cytokine synthesis - IC cytometry Cytokine secretion Cell-cycle/apoptosis Lymphocyte activation Cell division - ELISA, ELISPOT - DNA content - IN antigens - 3H-thymidine, CFSE, MTT The examination often requires specific Ag-Ab reactions (review/revise) THE SIGNAL INTENSITY IN THE METHODS BASED ON ANTIGEN-ANTIBODY INTERACTIONS IS PROPORTIONAL TO THE AMOUNT OF ANTIGEN PRESENT Enzyme activity is measured by the color reaction due to conversion of substrate in ELISA Similar principle applies to many other antibody-based detection methods High throughput screening methods based on antigen-specific antibodies (can be considered as proteomic methods) CYTOKINE ARRAY Simultaneous detection of multiple cytokines multiple antigen specific antibodies bound to a membrane (a kind of protein binding membrane as in WB) labeled antibody mixture (+) IL-2 IL-4 the sample which contains cytokines … … MIP3β IFN … ( Disadvantage: Relatively large sample volume is needed to cover the surface of the membrane -) “Sandwich” Dendritic cells were activated either by CD40L or by the combination of CD40L+SLAM molecules Réthi és mtsi. 2006 Any kind of antigen and modified antigens can be also examined: E.g.: Signalling of untreated and UV light irradiated cells examination with a “phosphoprotein intracellular signalling array kit” chemoluminescence / densitometry (+) (+) (+) (-) Protein array Phosphoprotein array signalling pathways High throughput cytokine examinations by flow cytometry (proteomics) It can be performed with small volumes (5-20ml) also Cytometric multiplex bead array (CBA) The cytokine capture beads are identified by their colour intensities IL-2 cytokine array CBA IL-4 IL-8 … … IL-12 IL-23 IL-17 … … Cytometric / multiplex bead array (CBA) Comparison of CBA with the sandwich ELISA Sandwich ELISA CBA IL-2 „reporter” antibody IL-2 bead with capture antibodies IL-4 IL-2 capture antibodies IFN sample cytokine concentration The cytokine concentration is proportional with the color intensity of the reporter antibody TNFα IL-6 IL-8 IL-12 IL-10 IL-1β 500pg/ml 250pg/ml 125pg/ml 62pg/ml 31pg/ml 16pg/ml cytokine standard serial dilution 8pg/ml 0 Cell signalling and protein modifications can be also examined by cytometric bead arrays (similarly to the protein arrays) • • • • phosophoproteins ubiquitinylation acetylation etc. Examination of the antigen-specific T-cells e.g.: monitoring the efficiency of a vaccination antigen specific T-cell T-cell clones with identical T-cell antigen receptors immunisation The specificity of the T-cell receptors (TCR) should be identified Antigen receptors can be identified with the antigen. TCR can be identified with the ligand: labelled MHC-peptid complex The interaction between the TCR and the MHC is too low affinity MHC T-cell receptors T-cell A single MHC molecule can only temporarily bind to a single TCR Multimeric MHC-peptid complex can have appropriate avidity for efficient binding MHC pentamer technics one unit of the pentamer peptide MHC self assembling coiled-coil-domain fluorescent label composed pentamer MHC pentamer binding to T-cell MHC pentamer T-cell receptors MHC-peptide oligomers have high avidity interactions with the specific TCRs MHC multimers could help revealing the antigen specific T cell numbers, which is useful in the estimation of the efficiency of new vaccination or T-cell therapeutic methods peptide-specific T-cell Launch pro5.exe short animation MHC dextramers – MHC/peptie complexes can be bound to dextrane polimers to form multimeric complexes MHC tetramers – avidin has tetrameric biotin binding domains, so it can bind 4 biotinylated MHC/peptide complexes https://www.benaroyaresearch.org/what-is-bri/scientists-andlaboratories/core-labs/tetramer-biomarker EBV BZLF-1 (RAKFKQLL/ HLA-B*0801)-specific T-cells (carriers: 90-95% of the normal healthy human population) MHC multimeric staining CMV-specific T-cells in a healthy HLA-A2 donor Healthy people can have high number of herpesvirus specific T cells. Latent infections keep the number of antigen specific memory/effector cells high. Influenza epitope (GILGFVFTL/ HLA-A0201)-specific (memory) T-cells in a healthy donor You should know the MHC specificity of the T cells to perform the examinations! (MHC restriction of the T cells) allél sequence Tumour (associated) peptide epitops A*0201 GVLVGVALI Carcinogenic Embryonic Antigen (CEA) 694-702 A*0201 LLGRNSFEV p53 261-269 A*0201 LLLLTVLTV MUC-1 12-20 A*0201 RLLQETELV HER-2/neu 689-697 A*0201 RMFPNAPYL Wilm's Tumour (WT1) 126-134 A*0201 SLLMWITQV NY-ESO-1 157-165 A*0201 STAPPVHNV MUC-1 950-958 A*0201 VISNDVCAQV Prostate Specific Antigen-1 (PSA-1) 154-163 A*0201 VLQELNVTV Leukocyte Proteinase-3 (Wegener's autoantigen) 169-177 A*0201 VLYRYGSFSV gp100 (pmel17) 476-485 A*0201 YLEPGPVTA gp100 (pmel17) 280-288 A*0201 YLSGANLNL Carcinogenic Embryonic Antigen (CEA) 571-579 A*0201 KVLEYVIKV MAGEA1 278-286 A*0201 KVAELVHFL MAGEA3 112-120 A*0201 KTWGQYWQV gp100 (pmel17) 154-162 A*0201 HLSTAFARV G250 (renal cell carcinoma) 217-225 A*0201 ILAKFLHWL Telomerase 540-548 Examples of some available human MHC/peptide pentamers You should know the HLA type of the investigated person allele sequence EBV epitope A*0201 CLGGLLTMV EBV LMP-2 426-434 A*0201 GLCTLVAML EBV BMLF-1 259-267 A*1101 IVTDFSVIK EBV EBNA-4 416-424 A*2402 TYGPVFMCL EBV LMP-2 419-427 B*0702 RPPIFIRRL EBV EBNA-3A 247-255 B*0801 FLRGRAYGL EBV EBNA-3A 193-201 B*0801 RAKFKQLL EBV BZLF-1 190-197 B*3501 HPVGEADYFEY EBV EBNA-1 407-417 A*0201 ILHNGAYSL HER-2/neu 435-443 allele sequence A*0201 IMDQVPFSV gp100 (pmel17) 209-217 Influenza A epitope A*0101 CTELKLSDY Influenza A (PR8) NP 44-52 A*0201 KIFGSLAFL HER-2/neu 348-356 A*0201 GILGFVFTL Influenza A MP 58-66 A*0201 LMLGEFLKL Survivin 96-104 A*0301 ILRGSVAHK Influenza A (PR8) NP 265-274 A*0201 ALQPGTALL Prostate Stem Cell Antigen (PSCA) 14-22 A*0201 CMTWNQMNL Wilm's Tumour (WT1) 235-243 A*0201 ELAGIGILTV MelanA / MART 26-35 allele sequence HIV epitope A*0201 FLTPKKLQCV Prostate Specific Antigen-1 (PSA-1) 141-150 A*0201 ILKEPVHGV HIV-1 RT 476-484 A*0201 GLYDGMEHL MAGEA-10 254-262 A*0201 KLTPLCVTL HIV-1 env gp120 90-98 A*0301 KQSSKALQR bcr-abl 210 kD fusion protein 21-29 A*0201 SLYNTVATL HIV-1 gag p17 76-84 A*0301 ATGFKQSSK bcr-abl 210 kD fusion protein 259-269 A*0201 TLNAWVKVV HIV-1 gag p24 19-27 A*0301 ALLAVGATK gp100 (pmel17) 17-25 A*0301 QVPLRPMTYK HIV-1 nef 73-82 A*2402 VYGFVRACL Telomerase reverse transcriptase (hTRT) 461-469 A*0301 RLRPGGKKK HIV-1 gag p17 19-27 A*2402 TYLPTNASL HER-2/neu 63-71 A*2402 RYLKDQQLL HIV-1 gag gp41 67-75 A*2402 TYACFVSNL Carcinogenic Embryonic Antigen (CEA) 652-660 B*0702 IPRRIRQGL HIV-1 env gp120 848-856 A*2402 TFPDLESEF MAGEA3 97-105 B*0702 TPGPGVRYPL HIV-1 nef 128-137 A*2402 EYLQLVFGI MAGEA2 156-164 A*2402 CMTWNQMNL Wilm's Tumour (WT1) 235-243 A*2402 AFLPWHRLF Tyrosinase 188-196 B*0801 GFKQSSKAL bcr-abl 210 kD fusion protein 19-27 B*0801 FLKEKGGL HIV-1 nef 90-97 B*0801 GEIYKRWII HIV-1 gag p24 261-269 B*2705 KRWIILGLNK HIV-1 gag p24 265-274 H-2Kd AMQMLKETI HIV-1 gag p24 199-207 MHC TYPING and some transplantation immunology Natural populations have multiple MHC isotypes and allelic variants human MHC antigens human leukocyte antigens (HLA) HLA typing polymorphic MHC I isotypes: HLA-A, HLA-B, HLA-C polymorphic MHC II isotypes: HLA-DP, HLA-DQ, HLA-DR laboratory mouse MHC antigens H-2 antigens H-2 typing MHC I: H-2K, H-2D, H-2L MHC II: H-2A (I-A), H-2E (I-E) (Laboratory animals are inbred and their MHC types are known) HLA typing human polymorphic isotypes: MHC I: HLA-A, HLA-B, HLA-C MHC II: HLA-DP, HLA-DQ, HLA-DR • used in organ/tissue transplantation Polimorphic isotypes have higher chance to differ between individuals The most polymorphic isotypes (HLA-B and HLA-DR) could cause most of the problems in the transplantation HLA-C is less polymorphic, less immunogenic, so it can have smaller negative effect on the success of the transplantation • can have diagnostic value Significant correlation can be shown between the presence of some HLA allelic variant and the incidence of diseases. The correlation can be either positive or negative (e.g.: autoimmune diseases, hypersensitivity, infections….) • as you seen before in connection with the MHC multimers, you can’t use some examination methods without prior typing the MHC of your subject Some term in connection with MHC types and transplantation: autologous – derived from the self/same organism (MHC identical) syngeneic – have the same MHC alleles (e.g. identical twins, identical mouse strains) allogeneic – have different MHC alleles (e.g. derived from an other person) xenogeneic – MHC and other genetic differences between species (e.g. “blood group” antigenic differences) Transplant reactions (antibody or T cell mediated effector functions) • Hyperacute rejection Pre-immunised state of the recipient: Presence of anti-MHC or anti blood group (AB0) antibodies (blood group mismatch) antibodies bind to the endothelial cells of the organ • activation of the complement system • FcR mediated reactions • trombosis • vascular necrosis • Acute rejection: - HLA-A, B, C, DR, DQ, DP differences - minor histocompatibility antigen differences allogeneic MHC or antigens can be recognised by T cells: Direct: T cells recognise allogeneic MHC expressing cells (CD8+ CTL cytotoxicity) Indirect: professional self APC present alloantigens from the graft (allogeneic MHC proteins can give rise peptides also) (CD4+ T cells: cytokine production, inflammation) therapy resistant INFLAMMATION, ORGAN REJECTION Diseases (autoimmune) HLA frequency sick control SLE DR3 B8 55 50 20 20 Hiydralazin induced lupus erythematosus DR4 73 32 DR3 B8 DR3 DR2 B7 B8 56 43 55 60 37 44 25 20 21 30 24 20 DR4 53 19 DR3 DR3 B8 DR3 B8 DR3 B8 DR3 DR7 B8 DR2 DR3 DR3 B8 B35 B27 DR4 72 49 40 70 46 70 50 79 60 68 88 81 82 75 70 79 95 24 22 21 20 23 20 22 22 15 22 29 20 20 22 15 9 20 Basedow-disease Chronic active hepatitis Sclerosis multiplex Myasthenia gravis Autoimmune IgA glomerulonephritis Type I diabetes Addison-disease Sjörgen-syndrome Coeliakia Goodpasture-syndrome IgA defficiency Dermatitis herpetiformis De Qervain-thyreoiditis Reiter-syndrome Felty-syndrome HLA allotípusok és betegségek közötti kapcsolatok Diseases Narcolepsy Bechterew-disease Adrenogenital syndrome salt wasting late form virilisating form Psoriasis vulgaris Idiopathic haemochromatosis Bechet-disease Gold induced thrombocytopenia Gold induced leukopenia Klinikai immunológia (II. klinikum) (OHVI 1990 szerk.: Szegedi, Gergely, Sipka, Szemere) Stenszky Valéria: Autoimmun betegségek genetikai vonatkozásai HLA frequency sick control DR2 B27 100 89 22 9 Bw47 B14 B5 Cw6 B13 B17 DR7 A3 B51 DR3 DR3 36 57 48 56 24 27 48 76 50 50 47 1 4 10 15 8 8 23 28 11 13 13 HLA typing methods: The classical immunology method: Serotyping Antibodies in the typing sera can recognise the HLA antigens on the cells. Different sera can be used to react with the isotypes of MHC I or MHC II. The sera can discriminate between different allelic types (allotypes). Classical complement activation pathway mediates the lysis of the recognised cells: If the typing serum don’t react with the cells there is no lysis or membrane damage The slightly damaged cells can be stained and the degree of damage observed by microscopy can get some “score” • Typing sera could be obtained from immunised persons in the past (e.g. women after multiple pregnancies or persons after blood transfer can be immunised by different MHC alleles) Monoclonal antibodies are used for the purpose recently. • Serum/antibody specificity and new HLA allelic variants are discussed / exchanged on international workshops • The quantity of the well characterised typing seran is limited typing is proceed in small volumes on microtiter plates (microcytotoxicity tests – Terasaki plates) HLA types described by the help of antibodies (or antibody containing typing antisera) are called HLA serotypes HLA serotypes: HLA-D (HLA-DR, DQ, DP): Dw „cellular HLA types” are described by T cell alloreactions Nomenclature for factors of the HLA system, 2010 Tissue Antigens 2010, 75, 291–455 (MLR – see it later) Some features of the serotyping • Serotyping identifies large “allelic groups” which contains similar alleles Genotyping could identify the exact allele, but the rapid serotyping narrows the possibilities • w – workshop labelling: non characterized, ambiguous alleles Their nomenclature can be changed in the future. Most weakly immunogenic HLA-C and HLA-DP alleles have only “workshop” typing sera, so the serotypes are also “w” labelled serotypes • Numbers in the parentheses can refer to cross reactivity with other typing serum, or can refer old “serogroups” which were discontinued after the exact genotyping. e.g. A9 A23, A24 (see it later) • MHC class II antigenes (HLA-DP, DQ, DR) can be found only on professional APC. Peripheral blood B cells are used for it. peripheral blood, Ficoll separation PBMC (peripheral blood mononuclear cells) PBMC, cheap nylon column enriched B cells (enriched B cells + EBV transformed, immortal B cell lines) Cellular reactions - Alloreactions MHC compatibility can be examined by mixed lymphocyte reactions (MLR). The presence of alloreactive T cells can be revealed by it. Mononuclear cells of the donor and the recipient can be mixed. Alloreactive T cells will be activated, and the proliferation can be examined by appropriate methods (e.g. 3H-thymidine incorporation) • Two way MLR – both persons’ T lymphocytes can respond: It can be important in the case of bone marrow transplantation to avoid graft versus host disease • One way MLR – one person’s lymphocytes are prevented in the proliferation (e.g. gamma-irradiation, Mitomycin C treatment) The percentage of the alloreactive lymphocytes can be very high (1-10%) The severe taboo mismatches can be screened with it Allotypes of the HLA-D (MHC II) isotypes (DR, DQ, DP) can be examined by T cells with known specific alloreactivity: cellular typing The cross reactions are rather frequent. “Dw” cellular types can be identified. (see the table on the 2nd slide above) (w ! – workshop, ambiguous types !) (The long term maintenance of the allospecific T cell lines are very difficult. The usage is very limited) Serotyping has limits: • cross reactions are frequent (both the (polyclonal) antibody cross reactivity and the similar epitopes of the MHC molecules should be considered) • there are few typing sera against the HLA-C, HLA-DP isotypes (low immunogenity) • small but important differences can’t be recognized by antibodies: e.g. the T cell epitops can be located inside the proteins which can’t be accessed by the antibodies Serology detects only the fragments of the full variability of HLA! Molecular (genetic) typing DNA sequencing has become wild-spread. Small sequence differences can be shown very easily. The DNA sequence differences can appear in the proteins: “missense” variants – can influence both T and B cell recognition “nonsense” variants – null alleles Non exonic variants can influence the expression of the alleles which also could influence the antigenity of the alleles Molecular typing • SBT (Sequence Based Typing) DNA sequencing can be used to reveal the full sequence of an MHC allele and able to identify small differences between sequences. Lots of new alleles were identified this way. MHC I exons: 1 2 3 MHC II 4 5 67 leader, signal protein domains α-chain 8 n.t. α1 α2 α3 1 2 4 56 leader, signal β1 tm c α1 α2 β1 α1 α3 β2 α2 7 n.t. α1 The exons encoding the most polymorphic α1 and α2 domains are examined in the routine typing (exon 2 and exon 3 in this example) 3 β2 α2 tm c β-chain α-chain The exons encoding the most polymorphic domains of the alpha and beta chains (α1 and β1 domains) are examined in the routine typing (exon 2 in this example) Molecular (genetic) typing • PCR-SSP (Sequence Specific Primer) Used for typing alleles with known sequences PCR examination with allele specific primer pairs recognizing allele specific HLA sequences. The PCR multiplied product can be detected in the agarose gel at a specific location. HLA-A* 02:01 02:02 02:03 … Molecular (genetic) typing • PCR-SSOP (Sequence Specific Oligonucleotide Probes) Labelled allele specific oligonucleotide sequences can hybridize to the DNA sample of the examined person. Used for typing alleles with known sequences The most widely used HLA screening/typing method • • • • The HLA region of the examined person is multiplied by PCR The products are bound to a surface (immobilisation on membrane or microtiter plate) The immobilised DNA can bind the allele specific labelled oligonucleotide probes (hybridisation) The label, as usual, can be radioactivity, fluorescence, or enzyme ( ELPHA) An example for PCR-SSOP: ELPHA (Enzyme Linked Probe Hybridization Assay) (1st step) - DNA isolation from PBMC - Amplification of the MHC II genes’ 2nd exons and the MHC I genes’ 2nd and 3rd exons by PCR. The primers are non allele specific and labelled with biotin DP DQ DR Multiplied MHC “gene loci” B C A ELPHA (Enzyme Linked Probe Hybridization Assay) (2nd step) • The PCR amplificated DNA are distributed on microtiter plates covered with streptavidine. The wells contain the allele sequence specific complementer oligonucleotide probes (SSOP). • The biotinylated DNA bind to the streptavidine. • The complementer sequences hybridize. Only the bound sequences remain in the wells after the washing. allele specific oligo biotinylated PCR product streptavidine The oligonucleotides are labelled/tagged. The tag is recognized by enzyme conjugated antibodies which could generate colorisation (The “tag” of the oligonucleotides should not be biotin, because the biotin is applied on the amplificated DNA. They can use other tags: e.g. digoxigenin or FITC) e.g. an HLA-A typing microtiter plate A B C HLA-A*02:76 D E HLA-A*24:34 F G H 1 2 3 4 5 6 7 8 9 10 11 12 Heterogeneity of the human MHC http://hla.alleles.org/ DNA sequencing The identified allele number is increasing year-by-year MHC allele frequency groups: common - 0.1% (in at least 1500 examined person of a population) well-documented - described at least five times in unrelated individuals rare - reported 1-4 times from unrelated individuals very rare - reported one time (common and well-documented alleles can be found in CWD HLA allele reports) Nomenclature of the HLA system (after 2010) Huge number of different alleles needs complex nomenclature http://hla.alleles.org/ • The international HLA workshops regularely discuss te new allele and the nomenclature. • The new alleles are published here: Tissue Antigens, Human Immunology, International Journal of Immunogenetics • Large reviews and databases help to understand the nomenclature and the “conversion” between the serotypic and the molecular nomenclature: Nomenclature for factors of the HLA system, 2010, Tissue Antigens 2010, 75, 291–455 Connections between the genetic typing and the serotyping The number after the asterisk is the “allele group” which usually corresponds the serotype: HLA-A*02 A2 * e.g.: Allele name before 2010 serotype There are exceptions: Allele name before 2010 serotype The A*24 allele group usually corresponds the A24(9) serotype But the A*24:19 allele can be identified with only the A9 specific typing serum The A9 serotype (and former allelic group) was separated to the new A*23 and A*24 allelic groups, so there is no A*09 anymore HYPERSENSITIVITY REACTIONS HYPERSENSITIVITY REACTIONS Innocous materials can cause hypersensitivity in certain individuals leading to unwanted inflammation damaged cells and tissues Non-proper reaction of the immune system to foreign substances Mainly harmless substances – after second or multiple exposure Different individuals respond differently to allergens / hipersensitising agents T cell response MHC dependence Atibody response generally needs also T cell activation ( MHC dependence) MHC allelic heterogeneity in the population Different response from different individuals AN OVERVIEW OF HYPERSENSITIVITY REACTIONS Type I. Type II. „immediate” Type IV. „late” Antibody mediated • • • • Type III. T cell mediated all start with sensitisation autoimmune diseases can be connected with them the effector mechanism are similar – so are the symptomps there are few clear types – lots of overlapping properties between the different types (Type I and Th2 Type IV can be connected; or Type IV neoepitops can induce Type II like antibody response also) TYPES OF ANTIBODY MEDIATED HYPERSENSITIVITY REACTIONS FcRIα) TYPE I HYPERSENSITIVITY REACTION ALLERGY (“Immediate” hypersensitivity reaction) SENSITISATION PROCESS Once sensitized (immunized), every following exposure to the allergen elicits the allergic reactions. ACUTE AND CHRONIC PHASE OF THE ALLERGIC RESPONSE Eosinophyls produces toxic materials tissue damage MAST CELL RESPONSE TO SURFACE FcεR I CROSSLINKING IgE a g b I I TT AA MM PLA2 foszfa tidil-kolin LYSO-PC arachidonsav Fc eRI I T A M MAPkináz I T A M Lyn II TT AA MM PIP2 Syk endoplazmás retikulum 2 Ca + 5-lipoxigenáz PI-PLCg DAG IP3 foszfolipid ciklooxigenáz Ca 2+ PGD2 citokin gének transzkripciója LTC4 NFAT AP-1 NF-k B PAF szekretoros granulum 2+ PKC Ca Ca 2+ proteinek (miozinkönnyűlánc) foszforilációja Ca 2+ szekréció PGD2 LTC4 LTD4 LTE4 LATE MEDIATORS (newly synthesized) mediátorok citokinek IL-3, IL-4, IL-5, IL-6 TNFa EARLY MEDIATORS (stored in granulums) Biogenic amins – histamine Enzymes – triptase, chymase, carboxypeptidase early (stored) mediators Examination of the mast cell function or the presence of antigen specific IgE antibodies in laboratory animals: Passive cutaneous anaphylaxis (PCA) Antigen specific IgE can be administered intradermally, locally to an animal (“local passive immunisation”) Few days later intravenuos antigen and stain solution are administered. (Evans-blue stain – can bind to albumin in the circulation) The small antigen can activate the sensitized mast cells locally at the places of the local passive immunisation. The IgE carrier mast cells can respond “immediately”. The locally released histamine activates the small capillaries and endothelial cells. The permeability is increased. The blue stain enters in the tissues which can be observed by naked eye. Mc-cpa−/− mast cells mount a normal passive cutaneous anaphylaxis reaction. Thorsten B. Feyerabend et al. Mol. Cell. Biol. 2005;25:61996210 Skin test of allergy Prick test MAST CELL DEGRANULATION, ALLERGIC REACTION IN THE SKIN OF A SENSIBILIZED INDIVIDUAL PRICK TEST Allergic reactions composed of immediate and late phase response some hours later late phase mediators can cause larger, long lasting edema ImmunoCAP Specific IgE Blood Test Allergen specific IgE can be shown from the blood similarly to the simple indirect ELISA method Anti-IgE Serum IgE Allergen Solid phase Short/Common ragweed (Ambrosia artemisiifolia) Short/Common ragweed (Ambrosia artemisiifolia) Green leaf back Mugwort (Artemisia vulgaris) White leaf back TYPE II HYPERSENSITIVITY IgG type antibodies bound to cell surface or tissue antigens (usually) • cells expressing the antigen become sensitive to complement mediated lysis or to opsonized phagocytosis • frustrated phagocytosis tissue damage • the antibody inhibits or stimulates target cell function no tissue damage (e.g. M. gravis receptor-blocking antibodies; (Basedow-) Graves disease TSH receptor stimulating antibodies) MECHANISMS OF TYPE II HYPERSENSITIVITY REACTIONS NK Mf Killing of target cell by effectormacrophage or NK-cell IgG ADCC IgG C' complement activation Killing of target cell by complementmediated lysis Receptor-specific autoantibody interferes with signal transduction DEVELOPMENT OF DRUG SENSITIVITY I. neoepitope! sensitisation DEVELOPMENT OF DRUG SENSITIVITY II. effector phase: TYPE III HYPERSENSITIVITY (Immune complex diseases) Antibodies binding to soluble antigens forming small circulating immune complexes which are deposited in various tissues Depends on: • Size of immune complexes • Antigen-antibody ratio (antigen excess in autoimmune diseases small complexes) • Affinity of antibody • Isotype of antibody (see: precipitation/agglutination) Large immuncomplexes are rapidly removed by phagocytic cells (FcR mediated) THE PROCESS OF TISSUE DAMAGE CAUSED BY IMMUNE COMPLEXES Antigen C' Immune complex Antibody Complementa ctivation (C3a , C5a ) PMN Chemotaxis C' Endothelium Ba sophil Ba sa l membra ne gra nulocyte Vessel wa ll Thrombocytes Deposition Blood vessel wall permeability Frustrated phagocytosis Vasoactive a mines Immune complexes activate the complement system, neutrophils, basophils and thrombocytes tissue penetrating anaphylatoxins (e.g. C5a) can activate mast cells also SYMPTOMES CAUSED BY TYPE III HYPERSENSITIVITY REACTIONS DEPEND ON THE SITE OF IMMUNECOMPLEX DEPOSITION vasculitis symptoms in serum sickness ARTHUS-REACTION • Localized Type III hypersensitivity • Local vasculitis develops as a result of immune complex deposition • Inhaled antigens (fungi, animal feces) may induce similar reaction in the lung: ‘Farmers lung’ and ‘piegeon-breeder’s lung’ • IgG type antibody DEPOSITION OF IMMUNE COMPLEXES IN THE SKIN OF SLE PATIENTS (Immunofluorescence) When immunofluorescence staining with an antibody to complement or immunoglobulin is performed, a brightly fluorescent signal staining the dermal epidermal junction is visible indicating immune complex deposition. Immunofluorescence staining pattern with antibody to IgG staining immune complexes at the dermal-epidermal junction. If such a pattern is seen only in skin involved by a rash, then the diagnosis is probably DLE, but if this pattern appears even in skin uninvolved by a rash, then the diagnosis is SLE. ANA Anti-nuclear antibody This is the so-called "nucleolar pattern" of staining in which the bright fluorescence is seen within the nucleoli of the Hep2 cells. This pattern is more suggestive of progressive systemic sclerosis. This is the so-called "rim" pattern that is more characteristic of SLE. This is the so-called "speckled" pattern of staining which is more characteristic of the presence of autoantibodies to extractable nuclear antigens, particularly ribonucleoprotein. This pattern is not very specific, but may be seen with an entity called "mixed connective tissue disease" which is a mix between SLE, scleroderma, and polymyositis, but without serious renal or pulmonary disease. The autoimmune diseases are very hard to classify, even for the experts. TYPE IV HYPERSENSITIVITY REACTION T CELL MEDIATED PROCESS (needs antigen presentation) IV-es típusú túlérzékenységi reakció (az effektor T sejtek alapján csoportosítva) Type IV hypersensitivity is mediated by T cells DELAYED-TYPE (TYPE IV) sensitisation HYPERSENSITIVITY DELAYED-TYPE (TYPE IV) HYPERSENSITIVITY effector phase DELAYED-TYPE HYPERSENSITIVITY (DTH) examination: e.g. tuberculin skin test TH1 from a previous immunization (memory) Tuberculin skin test Introduction of Ag Ag = antigen Purified protein derivate (PPD) CHEMICAL MEDIATORS OF DTH cytokine detection methods: ELISA…..etc DTH as a result of a contact-sensitizing agent* CONTACT DERMATITIS *a contact-sensitizing agent is usually a small molecule that penetrates the skin then binds to self-proteins, making them “look” foreign (T cell neoepitope) Plant containing contact sensitizing agent Poison ivy Anacardiaceae (family), Toxicodendron (genus) Toxicodendron radicans or Rhus toxicodendron (North America) Kontakt szenzitizálás hatására lipids with catechol ring (Urushiols): R = (CH2)14CH3 R = (CH2)7CH=CH(CH2)5CH3 R = (CH2)7CH=CHCH2CH=CH(CH2)2CH3 R = (CH2)7CH=CHCH2CH=CHCH=CHCH3 R = (CH2)7CH=CHCH2CH=CHCH2CH=CH2 etc. (neoepitopes) CELIAC DISEASE